Company news
Nexalin Technology, Inc. news in 2024
Nexalin Technology, Inc.'s news releases, calls and decks from 2024, newest first.
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
December 22, 2024
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
November 25, 2024
Nexalin Technology CEO Provides Letter to Shareholders
November 10, 2024
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
October 31, 2024
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
October 31, 2024
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
October 27, 2024
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
October 21, 2024
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
October 16, 2024
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
October 13, 2024
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
September 4, 2024
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
July 25, 2024
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
July 17, 2024
Nexalin Technology Announces Closing of $5.2 Million Public Offering
June 30, 2024
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
June 26, 2024
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
June 25, 2024
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
June 19, 2024
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
June 12, 2024
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
June 3, 2024
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
June 2, 2024
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
May 21, 2024
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
May 8, 2024
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
April 8, 2024
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
April 3, 2024
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
April 3, 2024
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
April 1, 2024
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
March 27, 2024
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
March 13, 2024
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
March 12, 2024
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
March 5, 2024
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
February 7, 2024
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
January 22, 2024
Nexalin Technology Unveils Next-Generation HALO™ Clarity
January 10, 2024
Decks in 2024
- Investor Presentation (December 2024)
Investor deck · 23 slides · December 2024
- Investor Presentation (June 2024)
Investor deck · 35 slides · June 2024